Skip to main content
Evidence Snapshot

Progesterone receptor

CHEMBL208 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:30:05Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL208
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Progesterone receptor as ChEMBL target CHEMBL208, mapped to UniProt P06401. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Progesterone receptor
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL208
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P06401
Progesterone receptor
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Progesterone receptor matters

As of 2026-09-13

Progesterone receptor is reviewed as Progesterone receptor (UniProt P06401); Progesterone receptor shows approved-linked disease relevance led by endometriosis. 5 more disease programs remain visible in the same review block.; 10 linked drugs keep this evidence frame grounded.; the current evidence base includes 29 approved drugs, 4676 compounds, and 627 assays, with lead potency reaching pChEMBL 10.7.

Disease context
endometriosis

Progesterone receptor shows approved-linked disease relevance led by endometriosis. 5 more disease programs remain visible in the same review block. 10 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include ASOPRISNIL, CYPROTERONE ACETATE, DANAZOL.

Start review with endometriosis because it currently carries approved-linked support. Linked drugs include ASOPRISNIL, CYPROTERONE ACETATE, DANAZOL, LEVONORGESTREL. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Approved-linked 10 linked drugs
Activity base
Portfolio and assay base

ChEMBL currently tracks 29 approved drugs, 4676 compounds, and 627 assays for this target. The dominant activity type is IC50. CHEMBL556891 is the current potency anchor at pChEMBL 10.7.

Use CHEMBL556891 as the tractability anchor when discussing potency (pChEMBL 10.7).

Activity source · ChEMBL 36 via Core Engine
29 approved pChEMBL 10.7
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Progesterone receptor matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P06401, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why endometriosis is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

4676
Total Compounds
627
Total Assays
29
Approved Drugs
IC50: 2214.0, KI: 804.0, EC50: 775.0, KD: 16.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL556891
 10.7 EC50 —
No preferred name
CHEMBL557293
 10.7 EC50 —
No preferred name
CHEMBL1276308
 10.7 IC50 Approved
No preferred name
CHEMBL490088
 10.6 IC50 —
No preferred name
CHEMBL556892
 10.4 EC50 —

Approved Drugs

Structure Compound First Approval
ULIPRISTAL ACETATE
CHEMBL260538
 2009
FLUTICASONE FUROATE
CHEMBL1676
 2007
FULVESTRANT
CHEMBL1358
 2002
DROSPIRENONE
CHEMBL1509
 2001
MIFEPRISTONE
CHEMBL1276308
 2000
BUDESONIDE
CHEMBL1370
 1994
FLUTICASONE PROPIONATE
CHEMBL1473
 1990
MOMETASONE FUROATE
CHEMBL1161
 1987
LEVONORGESTREL
CHEMBL1389
 1982
TAMOXIFEN
CHEMBL83
 1977
PROGESTERONE
CHEMBL103
 1976
NORETHINDRONE
CHEMBL1162
 1962
SPIRONOLACTONE
CHEMBL1393
 1960
MEDROXYPROGESTERONE ACETATE
CHEMBL717
 1959
DEXAMETHASONE
CHEMBL384467
 1958
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:30:05Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL208